Bristol-Myers Squibb (BMY) In-Depth Stock Report

Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.

Bristol-Myers Squibb (NYSE: BMY) is a diversified biopharmaceutical company with a broad portfolio spanning oncology, hematology, immunology, cardiovascular, and neuroscience therapeutics.

The company faces significant patent-cliff exposure on two of its largest legacy products, the blood thinner Eliquis and the cancer immunotherapy Opdivo, both of which face looming loss of exclusivity that will pressure revenue over the coming years.

Cobenfy (KarXT), approved for schizophrenia and representing a novel mechanism of action distinct from older antipsychotics, is Bristol-Myers Squibb's most closely watched new-launch asset and a key pillar of its "Growth Through Innovation" portfolio of newer products.

The Growth Through Innovation portfolio, comprising newer-launched and next-wave products beyond the legacy patent-cliff drugs, must scale quickly enough to offset the anticipated Eliquis and Opdivo revenue decline over the next several years.

This report walks through Bristol-Myers Squibb's live valuation across seven independent methods, its proprietary AI Score, a blended analyst price target, and a 5-year Monte Carlo simulation — then lays out the bull case, bear case, and the specific catalysts and risks most likely to move the stock, with particular attention to the pace of the Eliquis/Opdivo decline versus Cobenfy's launch trajectory.

The broader competitive and macro environment BMY operates in — context a pure valuation table can't convey on its own.

The branded biopharmaceutical industry faces a well-documented "patent cliff" cycle, in which blockbuster drugs lose exclusivity and face rapid generic or biosimilar erosion, forcing continuous pipeline reinvestment.

The schizophrenia and broader neuroscience/psychiatric drug market has seen limited mechanistic innovation in decades, creating an opportunity for differentiated new mechanisms of action like Cobenfy's muscarinic receptor approach.

Oncology immunotherapy remains a large but increasingly competitive category, with PD-1/PD-L1 inhibitors like Opdivo facing both patent expiration and competition from next-generation combination therapies.

Large biopharmaceutical companies increasingly rely on business development, including acquisitions and licensing deals, to refresh pipelines and offset patent-cliff revenue declines rather than relying solely on in-house R&D.

Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/BMY. Fields the pipeline doesn't return this load are omitted rather than shown blank.

Bristol-Myers Squibb generates revenue across oncology (led by Opdivo), cardiovascular (led by Eliquis), hematology, immunology, and neuroscience, with Cobenfy representing its newest major product launch.

Growth strategy centers on scaling Cobenfy and the broader Growth Through Innovation portfolio quickly enough to offset the anticipated revenue decline from Eliquis and Opdivo as both face loss of exclusivity.

A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.

How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.

Bristol-Myers Squibb has maintained a long history of dividend payments with periodic increases, reflecting management's commitment to capital returns even amid patent-cliff uncertainty.

Capital spending priorities include continued R&D investment in the Growth Through Innovation portfolio and business-development activity, including acquisitions and licensing deals, to refresh the pipeline.

The company has used its balance sheet for periodic acquisitions to bolster its oncology and neuroscience pipelines, alongside share buybacks as part of its broader capital-return approach.

Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.

Bristol-Myers Squibb's leadership has prioritized managing the Eliquis and Opdivo patent-cliff transition while scaling Cobenfy and the broader Growth Through Innovation portfolio as the central strategic priority.

Prospective investors should review the company's most recent proxy statement and 10-K for current board composition, executive compensation structure, and insider ownership details, since these are disclosed directly by the company and evolve over time rather than being estimated by third parties.

In-depth reports for other names in Bristol-Myers Squibb's comparable set.

Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.

Pfizer competes directly with Bristol-Myers Squibb in the anticoagulant market as its co-marketing partner on Eliquis, and separately across broader oncology and immunology categories.

Merck competes with Opdivo through its own leading PD-1 inhibitor, Keytruda, in a head-to-head rivalry that has shaped the oncology immunotherapy category for years.

Gilead Sciences and other oncology-focused biopharmaceutical companies compete with Bristol-Myers Squibb's cancer portfolio across overlapping indications.

Cobenfy's novel mechanism of action provides a differentiated competitive position in the schizophrenia market versus older-generation antipsychotics from a range of established and generic competitors.

A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.

Why this report is different from asking a general-purpose AI chatbot about the stock.

Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.